168 related articles for article (PubMed ID: 26497860)
21. Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma.
Takada M; Yasui T; Oka T; Shioyama W; Kuroda T; Nakai Y; Nishimura K; Mukai M; Fujita M
Int Heart J; 2018 Sep; 59(5):1174-1179. PubMed ID: 30158382
[TBL] [Abstract][Full Text] [Related]
22. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
23. The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China.
Zheng Y; Wang F; Wu G; Zhang L; Wang Y; Wang Z; Chen P; Wang Q; Lu J; Wang Y; Li P; Wang J; Lu X; Yuan J
Medicine (Baltimore); 2015 Dec; 94(49):e2222. PubMed ID: 26656362
[TBL] [Abstract][Full Text] [Related]
24. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
Vogelzang NJ; Pal SK; Signorovitch JE; Reichmann WM; Li N; Yang C; Liu Z; Perez JR; Jonasch E
Curr Med Res Opin; 2016; 32(4):741-7. PubMed ID: 26744781
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
[TBL] [Abstract][Full Text] [Related]
26. Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.
Fairfax BP; Pratap S; Roberts IS; Collier J; Kaplan R; Meade AM; Ritchie AW; Eisen T; Macaulay VM; Protheroe A
BMC Cancer; 2012 Dec; 12():590. PubMed ID: 23231599
[TBL] [Abstract][Full Text] [Related]
27. Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review.
Leonetti A; Bersanelli M; Castagneto B; Masini C; Di Meglio G; Pellegrino B; Buti S
Clin Genitourin Cancer; 2016 Aug; 14(4):277-83. PubMed ID: 26899142
[TBL] [Abstract][Full Text] [Related]
28. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
Eichelberg C; Heuer R; Chun FK; Hinrichs K; Zacharias M; Huland H; Heinzer H
Eur Urol; 2008 Dec; 54(6):1373-8. PubMed ID: 18692304
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study.
Gore ME; Jones RJ; Ravaud A; Kuczyk M; Demkow T; Bearz A; Shapiro J; Strauss UP; Porta C
BJU Int; 2017 Jun; 119(6):846-853. PubMed ID: 27981711
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis.
Omae K; Kondo T; Kennoki T; Takagi T; Iizuka J; Kobayashi H; Hashimoto Y; Tanabe K
Int J Clin Oncol; 2016 Feb; 21(1):126-32. PubMed ID: 26163345
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma.
Sil A; Das NK
Indian J Pharmacol; 2014; 46(3):334-6. PubMed ID: 24987183
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
33. Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival.
Yu X; Guo G; Li X; Zhang C; Huang L; Fang D; Song Y; Zhang X; Zhou L
Medicine (Baltimore); 2015 Aug; 94(34):e1361. PubMed ID: 26313773
[TBL] [Abstract][Full Text] [Related]
34. TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.
Verzoni E; Grassi P; Montone R; Galli G; Necchi A; Procopio G
Tumori; 2015; 101(6):701-3. PubMed ID: 26108242
[TBL] [Abstract][Full Text] [Related]
35. The role of tivozanib in advanced renal cell carcinoma therapy.
Escudier B; Porta C; Eisen T; Belsey J; Gibson D; Morgan J; Motzer R
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1113-1124. PubMed ID: 30084668
[TBL] [Abstract][Full Text] [Related]
36. First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience.
Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu GK; Lokanatha D; Jacob LA; Suresh Babu MC; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(4):626-630. PubMed ID: 30082547
[TBL] [Abstract][Full Text] [Related]
37. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
J Hum Hypertens; 2013 Oct; 27(10):601-11. PubMed ID: 23636006
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience.
Shetty AV; Matrana MR; Atkinson BJ; Flaherty AL; Jonasch E; Tannir NM
Clin Genitourin Cancer; 2014 Oct; 12(5):348-53. PubMed ID: 24565697
[TBL] [Abstract][Full Text] [Related]
39. Tyrosine kinase inhibitor induced pancreatitis.
Sevin A; Chen A; Atkinson B
J Oncol Pharm Pract; 2013 Sep; 19(3):257-60. PubMed ID: 23034406
[TBL] [Abstract][Full Text] [Related]
40. Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma.
Garuti F; Camelli V; Spinardi L; Bucci L; Trevisani F
Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27079903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]